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Henrik Holmstrøm, MD, PhD, e Stein Emil Vollset, MD, DrPH, a,f Grethe S. Tell, MPH, PhD, a,f and
Nina Øyen, MD, MPH, DrMed a,g Bergen, and Oslo, NorwayBackground The reasons for decreasing birth prevalence of congenital heart defects (CHDs) in several European
countries and Canada are not fully understood. We present CHD prevalence among live births, stillbirths, and terminated
pregnancies in an entire nation over a period of 16 years.
Methods Information on all births in the Medical Birth Registry of Norway, 1994-2009, was updated with information on
CHD from the hospitals' Patient Administrative Systems, the National Hospital's clinical database for children with heart
disease, and the Cause of Death Registry. Individuals with heart defects were assigned specific cardiac phenotypes.
Results Among 954,413 births, 13,081 received a diagnosis of CHD (137.1 per 10,000 births, 133.2 per 10,000 live
births). The prevalence per 10,000 births was as follows: heterotaxia, 1.6; conotruncal defects, 11.6; atrioventricular septal
defects, 5.6; anomalous pulmonary venous return, 1.1; left outflow obstructions, 8.7; right outflow obstructions, 5.6; septal
defects, 65.5; isolated patent ductus arteriosus, 24.6; and other specified or unspecified CHD, 12.7. Excluding preterm patent
ductus arteriosus, the CHD prevalence was 123.4 per 10,000; per year, the prevalence increased with 3.5% (95% CI 2.5-4.4) in
1994-2005anddeclinedwith 9.8% (−16.7 to−2.4) from2005onwards. SevereCHDprevalencewas30.7per 10,000; per-year
increase was 2.3% (1.1-3.5) in 1994-2004, and per-year decrease was 3.4% (−6.6 to −0.0) in 2004-2009. Numbers included
severe CHD in stillbirths and terminated pregnancies.
Conclusions The birth prevalence of CHD declined from around 2005. Specifically, the prevalence of severe CHD was
reduced by 3.4% per year from 2004 through 2009. (Am Heart J 2014;168:956-64.)Congenital heart defects (CHDs) are the most common
birth defects, reported to affect 5 to 10 per 1,000 live
births.1-5 These cardiac anomalies vary from minor
lesions without clinical significance to severe conditions
requiring extensive health care and with impaired
physical capacity and life expectancy. There is substantial
variation in the reported CHD prevalence by year of birth
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hfollow-up through adulthood is necessary for many
children with CHD and repeated surgical procedures
are often required. Because the etiology of CHD is largely
unknown, time trends and changing prevalence in
different populations might also give clues to differences
in risk factors.6
During the 1980s and 1990s, the recorded birth
prevalence of CHD increased substantially.3,5,7 Improved
diagnostic tools, such as high-quality ultrasound technol-
ogy, may have led to increased detection of the mild
anomalies in this time period. Although the septal defects
accounted for the largest proportion of the overall
increase in CHD prevalence,3,7,8 several studies also
reported an increased prevalence of severe heart
defects.3,4,6 However, recent studies have reported that
the CHD trend is changing. In Quebec, Canada,6 the
prevalence of severe heart defects started to decrease
from 1999. The authors suggested a preventive effect of
mandatory folic acid fortification of cereal products
introduced in Canada in 1998. In Atlanta, GA, however,
where folic acid fortification of flour was introduced at
the same time as in Canada, the CHD prevalence
continued to increase until 2005.7 Interestingly, in
European countries where there has been no mandatory
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European Surveillance of Congenital Anomalies (EURO-
CAT) registries 1990-20074 found a downward trend in
heart defect birth prevalence from 2004 onwards. A shift
from severe CHD in live births to severe CHD in
terminated pregnancies because of increasing availability
of prenatal diagnostics4 could also have contributed to
the drop in live birth prevalence of severe heart defects.
Norway's national health registers afford us the
opportunity to conduct a nationwide study of prevalence
and time trends of CHDs in live births, stillbirths, and
terminated pregnancies.
Methods
Data sources
The Norwegian Population Register has since 1965
registered demographic data and vital status on all
residents. The unique personal identification number
enables linkage of data between national registries and
other data sources.
The Medical Birth Registry of Norway (MBRN) was
established in 1967 and has since then recorded
information on all births (live births and stillbirths from
16th week of gestation, from 1999 also including
terminated pregnancies, and from 2002 all births from
12th week of gestation),10,11 including medical informa-
tion of the mothers' health before and during pregnancy,
the course of delivery, and the health of the newborn
child. The MBRN contains information on CHDs diag-
nosed shortly after birth based on reports from maternity
and pediatric wards.
The National Hospital's clinical database for children
with heart disease contains informationon all childrenwith
a heart condition who have been examined by a pediatric
cardiologist or have received surgery or intervention at the
National Hospital since 1992.12 The National Hospital
conducted about 80% of congenital heart surgeries in
Norway before 2004 and virtually all thereafter.13
The multipurpose research project Cardiovascular
Disease in Norway14 established in collaboration be-
tween the University of Bergen and the Norwegian
Knowledge Centre for the Health Services has retrieved
information on cardiovascular diseases including CHDs
from the electronic Patient Administrative System (PAS)
of all somatic hospitals in Norway, 1994-2009.15 Up to 20
discharge diagnoses for each hospital stay, as well as
information about diagnostic and surgical procedures, are
included in the database.
The Cause of Death Registry contains information about
the underlying cause of death and up to 6 contributing
causes of death, as recorded from the death certificate.
Study population
All births in Norway registered in The Medical Birth
Registry from 1994 through 2009 were followed until31 December 2009 for information on CHDs registered in
the hospitals' PAS and until 31 December 2010 for the
Medical Birth Registry, the National Hospital's clinical
database for children with heart disease, and the Cause of
Death Registry.
Case ascertainment and classification of CHDs
Information on individuals with CHD was ascertained
from 4 data sources: (1) the National Hospital's clinical
database for children with heart disease by van Mierop
codes 100, 110, 120, 200, 210, 1002 to 744216,17 and
International Classification of Diseases 10th Revision
(ICD-10) codes Q20.0 to Q26.9, Q89.3; (2) the PAS by
ICD-9 codes 745.0 to 747.4, 759.3 from 1994 through
1998, and ICD-10 codes Q20.0 to Q26.9, Q89.3 from 1999
onwards; (3) the Medical Birth Registry by ICD-8 codes
746.0 to 747.4, 759.0 from 1994 through 1997, and ICD-
10 Q20.0 to Q26.9, Q89.3 from 1997 onwards; and (4)
the Cause of Death Registry by ICD-9 745.0 to 747.4,
759.3 from 1994 through 1995, and ICD-10 Q20.0 to
Q26.9, Q89.3 from 1996 onwards.
According to this procedure, we identified 16,365
children with codes for CHD. Among them, we excluded
heart conditions likely to be physiologically normal, such
as 1,727 cases with untreated isolated patent ductus
arteriosus (PDA) without mention of the diagnosis after 6
weeks postnatal age; 1,061 untreated isolated atrial septal
defects (ASDs) without recording of the diagnosis after 6
weeks (likely persistent foramen ovale); 151 isolated
valvular pulmonary stenoses (vPS) without the diagnosis
after 6 weeks (likely normal high flow in the pulmonary
artery), and 344 cases with a combination of these
conditions, leaving 13,082 children with CHD for
phenotype classification.
Most children with CHD were registered in several data
sources: 36.5% in 2 sources, 14.9% in 3 sources, and 1.2%
in 4 sources. When assigning fetuses or children with
CHD into cardiac phenotypes, diagnosis codes were first
selected from the National Hospital's clinical database
(48.0% of the children), then the first entry in the PAS
(36.1%), with the priority for diagnoses from the
university hospitals with facilities for pediatric cardiac
surgery and invasive procedures, the Medical Birth
Registry (15.2%), and the Cause of Death Registry (0.7%).
Children with CHD codes were classified into cardiac
phenotypes as used by Botto et al,2,18,19 Øyen et al,2 and
recently by Liu et al,20 listing the diagnoses in order of
priority as follows: heterotaxiawith or without any other
heart defect; conotruncal defect (d-transposition of the
great arteries [TGA] or tetralogy of Fallot [ToF] with or
without atrioventricular septal defect [AVSD], double
outlet right ventricle [DORV], conoventricular ventricle
septum defect [VSD], pulmonary atresia [PA], or valvular
pulmonary atresia [vPA] with VSD [regarded as ToF
anatomy], truncus arteriosus, interrupted aortic arch
[IAA] type B or type C); AVSDwith or without anomalous
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or partial APVR; left ventricle outflow tract obstruction
(LVOTO) (coarctation of aorta [CoA] or aortic valve
stenosis [vAS] with or without VSD, hypoplastic left heart
syndrome [HLHS]); right ventricle outflow tract obstruc-
tion (RVOTO) (hypoplastic right heart syndrome [HRHS],
tricuspid atresia, Ebstein anomaly, PA or PvA with intact
ventricular septum, and vPS with or without septal
defects]; septal defects (VSD only, ASD only and recorded
from postnatal age 6 weeks, VSD and ASD only); other
complex heart defect (single ventricle, congenital cor-
rected transposition of the great arteries); PDA at
postnatal age N6 weeks or with surgical correction, in
live births with gestational age ≥37 weeks, or with
gestational age b37 weeks (preterm PDA); other specified
heart defect (eg, isolated valvular malformations not
classified as LVOTO or RVOTO and venous malforma-
tions); and unspecified heart defect. To the last category,
we added 89 children who had been registered with
diagnosis codes for lethal conditions and alive at age 2
years, but without registered heart surgery or invasive
procedure, assuming the heart defect was misclassified.
Severe CHD was defined as heterotaxia, conotruncal
defect, AVSD, APVR, LVOTO, RVOTO (except valvular
pulmonary stenosis), or other complex heart defect. In a
subanalysis, VSDs were divided into those corrected with
a percutaneous or surgical procedure and those without
such procedures.
Information on chromosome aberrations was retrieved
using ICD codes (eighth revision 759.3-759.5, ninth
revision 758.0-759.9, 10th revision D82.1, Q90.0-Q99.9)
and van Mierop codes (8000-8004, 8009-8025, 8072) in all
data sources. In addition, we searched for notes
indicating chromosomal disorders in text entry fields in
the National Hospital's clinical database for children with
heart disease, and Down syndrome registered in the
Medical Birth Registry of Norway. The CHD children with
extracardiac malformations were identified by ICD codes
(eighth revision 740.0-745.9, 748.0-756.9, 759.8-759.9,
ninth revision 740.0-744.9, 748.0-756.9, 759.0-759.9, 10th
revision Q00.0-Q18.9, Q30.0-Q89.9) and van Mierop
codes (8041-8053, 8066, 8074-8076, 8079, 8099), in
addition to selected congenital malformations registered
in MBRN. The categories chromosomal aberrations and
extracardiac malformations were not mutually exclusive.
The age at diagnosis was set to 0 day if the cardiac
defect was reported from the maternity ward, otherwise,
the age at the first hospitalization reporting CHD, or the
age at a cardiac procedure.
Statistical analysis
Birth prevalence was reported as number of persons
affected with CHD per 10,000 births (live births,
stillbirths, and terminated pregnancies) for the entire
period 1994-2009. Then, the prevalences of severe
defects combined, VSD, ASD, and PDA were calculatedby year of birth. Next, we modeled annual CHD
prevalence with The National Cancer Institute's Joinpoint
Regression Program version 4.0.47,21 to estimate annual
percent change (APC) with 95% CIs using the best fitting
model. And finally, the yearly prevalence of severe
defects was stratified on type of birth, that is, live birth
(singleton or multiple birth) with isolated severe heart
defect, live birth with severe heart defect and extra-
cardiac defect, stillbirth with severe heart defect, and
terminated pregnancy with diagnosed severe heart
defect. The median age at diagnosis was calculated for
the period 1994-2009 for severe CHD, ASD, and VSD.
Cumulative percentile curves for diagnosis were calcu-
lated at age 1, 7, 30, 180, 365, and 730 days for severe
CHD, and VSD, for the period 2004-2008. The data
linkage and all calculations were performed with SAS
(version 9.3; SAS Institute Inc, Cary, NC).Results
Among 954,413 births registered in the Medical Birth
Registry 1994-2009, we identified 13,081 individuals with
one or more CHDs; the overall birth prevalence was
137.1 per 10,000 (Table I). After excluding isolated PDA
in preterm births (gestational age b37 weeks), the birth
prevalence of CHD was 123.4 per 10,000. Congenital
heart defects were more frequent in girls, with birth
prevalence of CHD 136.2 per 10,000 (excluding preterm
PDA 123.3 per 10,000), compared to 131.1 per 10,000
(excluding preterm PDA 116.6 per 10,000) in boys (P b
.05). Severe CHD was found in 2,930 births, with an
overall prevalence of 30.7 per 10,000 births and 28.3 per
10,000 live births.
The most common cardiac defects were isolated septal
defects; the birth prevalencewas 65.5 per 10,000 (Table I).
Around three-quarters of these were VSDs, with 48.4
per 10,000 births. The prevalence of conotruncal defects
was 11.6 per 10,000; the most frequent was TGA, 3.5,
and ToF, 2.7 per 10,000. Left ventricular outlet tract
obstructions accounted for 8.7 per 10,000, including
HLHS, 2.6, vAS, 3.0, CoA, 3.0, and IAA type A, 0.1 per
10,000, and right ventricular outlet tract obstructions 5.6
per 10,000, among these HRHS, 0.9, Ebstein anomaly,
0.7, and vPS, 3.6 per 10,000. The prevalence of AVSDwas
5.6, of APVR 1.1, and of heterotaxia 1.6 per 10,000 births.
Other complex heart defects were found in 0.2 per
10,000. Isolated PDA had a prevalence of 24.6 per
10,000. In term births, prevalence of isolated PDA was
10.9 per 10,000. Other specified CHD was found in 6.6,
and unspecified CHD in 6.1 per 10,000 births.
The live birth prevalence of CHD was 133.2 per 10,000
and excluding preterm PDA 119.4 per 10,000, whereas
the prevalence of CHD among stillbirths or pregnancies
terminated for medical reasons was more than 3 times as
high, with a prevalence of 478.1 per 10,000 (Table I).
Specific cardiac phenotypes, such as heterotaxia,
Table I. Prevalence of CHDs in Norway, 1994-2009
Heart defect
phenotype
All births n = 954413 Live births n = 943871
Stillbirths/terminated
pregnancies
n = 10542
n Prevalence⁎ n Prevalence† n Prevalence‡
Any CHD 13081 137.1 12577 133.2 504 478.1
CHD excl. preterm PDA 11776 123.4 11272 119.4 504 478.1
Heterotaxia 149 1.6 133 1.4 16 15.2
Conotruncal defect 1110 11.6 1040 11.0 70 66.4
TGA 331 3.5 308 3.3 23 21.8
ToF 258 2.7 243 2.6 15 14.2
DORV 79 0.8 66 0.7 13 12.3
Other conotruncal§ 442 4.6 423 4.5 19 18.0
AVSD 530 5.6 492 5.2 38 36.0
APVR 107 1.1 107 1.1 0 0.0
LVOTO 830 8.7 722 7.6 108 102.4
HLHS 244 2.6 154 1.6 90 85.4
CoA 288 3.0 273 2.9 15 14.2
Valv. aortic stenosis 290 3.0 287 3.0 3 2.8
IAA A 8 0.1 8 0.1 0 0.0
RVOTO 532 5.6 506 5.4 26 24.7
HRHS 82 0.9 66 0.7 16 15.2
Ebstein 64 0.7 57 0.6 7 6.6
vPS 348 3.6 347 3.7 1 0.9
Other RVOTO∥ 38 0.4 36 0.4 2 1.9
Septal defect, isolated 6248 65.5 6113 64.8 135 128.1
ASD 1350 14.1 1342 14.2 8 7.6
VSD 4620 48.4 4506 47.7 114 108.1
VSD + ASD 189 2.0 179 1.9 10 9.5
Unsp. septal defect 89 0.9 86 0.9 3 2.8
Other complex CHD 20 0.2 20 0.2 0 0.0
Isolated PDA¶ 2345 24.6 2345 24.8 0 0.0
At term gestation 1040 10.9 1040 11.0 0 0.0
Preterm gestation 1305 13.7 1305 13.8 0 0.0
Other specified CHD 632 6.6 597 6.3 35 33.2
Unspecified CHD 578 6.1 502 5.3 76 72.1
Associations:
Conotruncal + AVSD 16 0.2 15 0.2 1 0.9
Septal + LVOTO 79 0.8 78 0.8 1 0.9
Septal + RVOTO 99 1.0 99 1.0 0 0.0
⁎ Prevalence per 10,000 births (live births, stillbirths, terminated pregnancies) registered in the Medical Birth Registry.
† Prevalence per 10,000 live births.
‡ Prevalence per 10,000 stillbirths and terminated pregnancies.
§ Truncus arteriosus, conotruncal VSD, aortopulmonary window, IAA type B or C.
∥Valvular pulmonary atresia, arterial pulmonary atresia.
¶ PDA recorded after 6 weeks of age or surgically treated.
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prevalence in stillbirths/terminated pregnancies.
In Table II, the distribution of cardiac phenotypes was
shown for multiple birth pregnancies, in children with a
chromosomal aberration, and in children with extracar-
diac birth defects. Among all births with CHD, 8.6% was
part of a multiple-birth pregnancy, 10.6% had been
diagnosed with a chromosomal aberration, and 21.0%
had extracardiac defects. For example, chromosomal
aberrations were frequent with AVSD, and extracardiac
defects with heterotaxia and conotruncal defects.
In Figure 1, the prevalences of severe CHD, ASD, VSD,
PDA, and the remaining defects (vPS, other specified CHD,and unspecified CHD) were presented by year of birth.
From 1994 until the beginning of the 2000s, all defects
increased in prevalence. Ventricular septal defects had the
most marked increase, with roughly doubled prevalence
from 1994 to 2007. The prevalence of repaired VSD was
stable with a mean prevalence of 5.5 per 10,000
throughout the entire study period 1994-2009 (not
shown in figure). Median age at diagnosis for ASD was
323 days; whereas for VSD, PDA, and severe CHD, it was 0
days, that is, diagnosed before leaving the maternity ward.
TheVSDdiagnosiswas registered before age 30days in 92%
of the cases, before 6 months in 97%, and within the first
year of life in 98% of the VSDs. For severe defects, the
Table II. Multiple birth and extracardiac defects in children with CHD, Norway 1994-2009⁎
Heart defect
phenotype
All births Multiple birth
Chromosomal
aberrations
Extracardiac
malformations
n n (%) n (%) n (%)
Any CHD 13081 1123 (8.6) 1389 (10.6) 2746 (21.0)
CHD excl. preterm PDA 11776 688 (5.8) 1365 (11.6) 2487 (21.1)
Heterotaxia 149 7 (4.7) 17 (11.4) 135 (90.6)
Conotruncal defect 1110 45 (4.1) 172 (15.5) 349 (31.4)
TGA 331 4 (1.2) 21 (6.3) 66 (19.9)
ToF 258 15 (5.8) 50 (19.4) 89 (34.5)
DORV 79 2 (2.5) 12 (15.2) 38 (48.1)
Other conotruncal† 442 24 (5.4) 89 (20.1) 156 (35.3)
AVSD 530 23 (4.3) 299 (56.4) 134 (25.3)
APVR 107 4 (3.7) 7 (6.5) 33 (30.8)
LVOTO 830 50 (6.0) 89 (10.7) 176 (21.2)
HLHS 244 9 (3.7) 18 (7.4) 47 (19.3)
CoA 288 25 (8.7) 42 (14.6) 70 (24.3)
Aortic stenosis 290 16 (5.5) 28 (9.7) 58 (20.0)
IAA A 8 0 (0.0) 1 (12.5) 1 (12.5)
RVOTO 532 31 (5.8) 35 (6.6) 125 (23.5)
HRHS 82 4 (4.9) 6 (7.3) 26 (31.7)
Ebstein 64 0 (0.0) 3 (4.7) 9 (14.1)
vPS 348 25 (7.2) 24 (6.9) 82 (23.6)
Other RVOTO‡ 38 2 (5.3) 2 (5.3) 8 (21.1)
Septal defect, isolated 6248 390 (6.2) 582 (9.3) 1048 (16.8)
ASD 1350 110 (8.1) 183 (13.6) 326 (24.1)
VSD 4620 264 (5.7) 317 (6.9) 641 (13.9)
VSD + ASD 189 10 (5.3) 77 (40.7) 75 (39.7)
Unsp. septal defect 89 6 (6.7) 5 (5.6) 6 (6.7)
Other complex CHD 20 0 (0.0) 1 (5.0) 6 (30.0)
Isolated PDA§ 2345 473 (20.2) 81 (3.5) 471 (20.1)
At term gestation 1040 38 (3.7) 57 (5.5) 212 (20.4)
Preterm gestation 1305 435 (33.3) 24 (1.8) 259 (19.8)
Other specified CHD 632 65 (10.3) 37 (5.9) 128 (20.3)
Unspecified CHD 578 35 (6.1) 69 (11.9) 141 (24.4)
Associations:
Conotruncal + AVSD 16 0 (0.0) 6 (37.5) 6 (37.5)
Septal + LVOTO 79 8 (10.1) 18 (22.8) 25 (31.6)
Septal + RVOTO 99 5 (5.1) 7 (7.1) 29 (29.3)
⁎All live births, stillbirths, and terminated pregnancies registered in the Medical Birth Registry.
† Truncus arteriosus, conotruncal VSD, aortopulmonary window, IAA type B or C.
‡Valvular pulmonary atresia, arterial pulmonary atresia.
§ PDA recorded after 6 weeks of age or surgically treated.
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sis were 85%, 94%, and 95%, respectively.
In Figure 2, we plotted the prevalence of any type CHD
(excluding preterm PDA), severe CHD, VSD, and ASD for
all births, including stillbirths and terminated pregnan-
cies. Using the Joinpoint Regression Program, the best fit
for time trend change was identified. Among all births,
the annual increase in total CHD prevalence was 3.5%
(95% CI 2.5-4.4) until 2006; thereafter, the prevalence
decreased with 9.8% per year (−16.7 to −2.4). Severe
CHD prevalence showed an annual increase of 2.3% (1.1-
3.5) until 2004 and an annual decrease of 3.4% (−6.6 to
0.0) thereafter. The prevalence of ASD increased with
5.7% (3.2-8.3) per year until 2005 and then decreased
with 12.0% (−21.3 to −1.9) per year. Ventricular septaldefect prevalence increased with 5.4% (4.0-6.8) per year
until 2007 and then showed a marked but nonsignificant
annual decrease of 18.6% (−36.7 to 4.6) the last 2 years of
follow-up. Among live births only (not shown in the
figure), the APC for any type CHDwas 3.5% (2.4-4.7) until
2005 and −7.5% (−12.2 to −2.4) thereafter; and for severe
CHD, the APC was 1.8% (0.2-3.4) until 2003 and −4.6%
(−7.3 to −1.8) thereafter. The time trend curve for
severe CHD in live births only did not differ much from
the severe CHD time trend in all births.
In Figure 3, the annual birth prevalence of severe CHD
in Figure 2 was classified into combinations of birth type,
plurality (singletons, multiples), and the presence of
extracardiac birth defects and/or chromosomal aberra-
tions. The live birth prevalence of singletons with severe
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Volume 168, Number 6CHD but without extracardiac defects or chromosomal
disorders was around 15 per 10,000 births, with a
decreasing trend from around 1999 (blue color). Next,
the live birth prevalence of twins or triplets with isolated
CHD constituted a very small fraction of the total severe
CHD prevalence (purple color). The prevalence of live
births with severe CHD and extracardiac defects/
chromosomal disorders ranged 10 to 14 per 10,000 (red
color). Finally, the prevalences for severe CHD in
stillbirths and terminated pregnancies increased from
0.9 per 10,000 total births in 1994-1997 to 1.6 in 1998-
2001, 3.2 in 2002-2005, and 5.1 in 2006-2009; the overall
severe CHD prevalence was 2.7 per 10,000 births (green
color). The proportion of terminated pregnancies and
stillbirths in births with severe CHD increased from 1994
through 2009; among the total numbers of severe CHD,
affected stillbirths and terminated pregnancies combined
(n = 257) constituted 8.8%: 3.0% in 1994-1997, 5.0% in
1998-2001, 9.8% in 2002-2005, and 16.9% in 2006-2009 (P b
.001).
Discussion
In this nationwide study of CHDs, we identified
N13,000 individuals with a CHD among 954,500 live
births, stillbirths, and terminated pregnancies registered
in the Medical Birth Registry of Norway from 1994 to
2009, yielding a national CHD prevalence of 137.1 perB
te
is
(h
e
in
p
P10,000. There was a significant increase in the prevalence
of CHD until 2005, followed by a significant decrease in
prevalence, both for total CHD and for severe CHD.
The overall prevalence of CHD in the present study was
higher than that reported in similar studies from
Denmark, other European countries, and Atlanta,
GA.3,4,7 In the Danish study,3 the overall prevalence
excluding isolated PDA in preterm infants was 103.2 per
10,000 live births versus 123.4 in our study. It is primarily
the prevalence of septal defects, particularly VSD, that
was higher in the present study, whereas the overall
prevalence of severe defects was similar to our findings.
The Danish study also reported an increasing prevalence
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Norway, 1994-2009. Severe heart defects were heterotaxia, cono-
truncal defect, AVSD, APVR, LVOTO, RVOTO (except valvular
pulmonary stenosis), and other complex heart defects.
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December 2014of severe heart defects from 1977 to 2005, like the present
study. A Canadian study,6 which included children born in
Quebec with selected severe CHDs (ToF, endocardial
cushion defects, univentricular hearts, truncus arteriosus,
transposition complexes) in the period 1990-2005, report-
ed a prevalence of 15.7 per 10,000 births, which is similar
to the prevalence of the corresponding defects in our study
and in Denmark. However, the study from EUROCAT,
covering 29% of the European birth population, reported
considerably lower prevalence of the severe CHD (single
ventricle, HLHS, HRHS, Ebstein anomaly, tricuspid atresia,
vPA, truncus arteriosus, AVSD, ToF, vAS, TGA, TAPVR,
CoA), 17.7 per 10,000,4 as compared to the present study,
30.7 per 10,000. Although the severe CHD prevalence was
lower in the EUROCAT study, the pattern of time trends
was similar to the present studywith an increase from1990
to 2004 and a decrease thereafter. The study from Atlanta7
also reported lower birth prevalence of total CHD and
severe CHD, 67.7 and 24.9 per 10,000, respectively, in the
period 1978-2005.As suggested in the previous studies,3,7,8 the increasing
prevalence of minor CHD may be partly explained by
improved diagnostic equipment. This applies primarily to
the period before year 2000. The continued increase of
both minor and severe CHD until 2006, however, has
most likely other explanations. We cannot rule out that
the CHD prevalence increase could partially be explained
by improved reporting of birth defects. In 1999, the
Medical Birth Registry implemented a revised notification
form, which may have led to higher quality of birth defect
reporting, including both mild and severe CHD. Manda-
tory reporting to MBRN of terminated pregnancies was
implemented: from 1999 to 2001 for pregnancies after
16th gestational week and from 2002 after 12th
gestational week.11 This can explain some of the increase
in severe CHD from 1994 to 2004.
After the mid-2000s, the prevalence of CHD declined,
most markedly for VSD; but also severe defect prevalence
declined. The prevalence of CHD could have been
underestimated in the last period because of shorter
follow-up time. However, VSD demonstrates a distinct
murmur usually detected at the maternity ward or the
child health clinic, also reflected in our study; 94% of the
VSDs had been diagnosed before age 6 months. The large
VSD decline the last 2 years of the study period likely
represented a true decrease. Most severe defects are
symptomatic in early life; in the present study, 94% were
diagnosed before 6 months of age. Therefore, the
declining prevalence of severe CHD from 2005 through
2009 cannot be fully explained by incomplete case
ascertainment due to a shorter follow-up of births in the
late period. We acknowledge that ASD, with a median age
at diagnosis of 323 days, could have been underestimated
in the last period.3
At present, the reasons for the decline of CHD
prevalence in Norway from the mid-2000-ies are un-
known. One explanation for the recent decrease in CHD
prevalence in Norway, as in other European countries
and Canada, could be an increased intake of folic acid in
fertile women. In 1998, food fortification of folic acid was
introduced in both Canada and Atlanta, GA, whereas in
the European countries, including Norway, official
authorities only recommended intake of folic acid
supplements for women planning a pregnancy and
early in pregnancy.22 Prenatal vitamin supplementation
policy in our study population has been unchanged since
1999. However, the uptake of the recommendations,
reflected by an increasing use of preconception folic acid
supplementation in Norway, from 5% to 26% in the
period 1999-2007,23 could explain the temporal decrease
in CHD prevalence reported in our study, assuming a
causal association between folic acid intake and CHD.24
In Canada, the decreasing prevalence of severe CHD from
1999 coincided with the implementation of food
fortification of folic acid. Interestingly, the severe CHD
reduction was delayed in Europe starting from the mid-
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intake of supplements containing folic acid among
women in Europe from the end of the 1990s.4,22
However, in Atlanta, GA, the severe defect prevalence
continued to increase until 20057 despite the mandatory
folate fortification of staple food beginning in 1998.
Alternative explanations for the recent decreasing
prevalence of severe CHD in Canada and Europe could
be other preventive factors, for example, cessation of
maternal smoking,25 or better monitoring of women with
diabetes26 or other chronic diseases, or maybe a
reduction in consanguineous marriages,27 which are
known to be associated with increased birth defect risk.
However, in the present study, the births among first-
generation immigrants with a high proportion of first-
cousin marriage28 amounted only to 1.1% of all births,
with an overall CHD prevalence of 165.8 per 10,000
births. Therefore, a change in consanguineous marriages
cannot explain the declining prevalence of CHD in
Norway. Finally, we cannot rule out the possibility of
random fluctuation; surveillance of CHD remains impor-
tant in the future.
A limitation of the present study was a possible
misclassification of diagnosis codes for CHD because
reviewing the medical records for 13,000 patients was
not feasible. Besides, we were not allowed by the Ethics
Committee to investigate individual medical records.
However, almost half of the cases and nearly all the
severe defect cases were retrieved from the National
Hospital's clinical database for children with heart disease
(NHCD). Senior pediatric cardiologists have regularly
entered and updated codes for heart defect diagnoses and
procedures into this clinical database, which has
minimized the possibility of misclassification of severe
defects. Furthermore, in the PAS, we selected diagnosis
codes from the university hospitals with facilities for
pediatric cardiology surgery and invasive procedures.
Finally, we cross-checked diagnosis codes in all 2,999
individuals notified with lethal conditions against their
survival status at age 2 years and surgery or procedure
codes, and identified only 89 (2.8%) misclassified severe
defect cases, which we placed in the unspecified CHD
category. Congenital heart defects with chromosomal
aberrations and/or extra-cardiac defects could have been
missed if the cardiac defect was not coded, for example,
in stillbirths or terminated pregnancies. However, the
proportions of chromosomal aberrations (10.6%) and
extracardiac defects (21.0%) were comparable to findings
from Denmark (7.0% and 22.3%).3 There was a risk of
including physiological heart conditions notified shortly
after birth. To avoid this, untreated ASD, PDA, and vPS
only recorded the first 6 postnatal weeks were excluded.
Some minor CHDs could have been missed because
outpatient clinics' data were only included from the
National Hospital's clinical database for children with
heart disease. Considering the high prevalence of minorheart defects in the present study, as compared with
previous studies, we consider the possible missing
outpatient minor defects of little importance.
The strength of the present study was the virtually
complete registration of both severe and minor CHD,
including cardiac defects in terminated pregnancies,
ascertained through 4 national health and administrative
registers. This is possible due to the unique personal
identification number given shortly after birth, allowing
follow-up through life. Because medical care for children
is free in Norway and health care is highly developed,
nearly all children with CHD are diagnosed at an early
age. Finally, the hierarchical structure of our classification
system assigning individuals with multiple heart defects
to only one cardiac phenotype precluded counting these
individuals several times, thus avoiding an overestimation
of the total prevalence.
In conclusion, in the present population-based study,
we found increasing prevalence of severe CHD from
1994 until 2005 and decreasing prevalence thereafter,
corresponding to findings in European and Canadian
studies. Although there was an increasing practice of
pregnancy termination of fetuses with severe CHD, this
contributed little to the time trends in CHD prevalence in
Norway. The reasons for the downward change in time
trends of CHD and severe CHD from the mid-2000s are
unknown but seem related to factors not only changing in
Norway. Suggested changes in maternal risk factors, such
as an increasing use of folic acid supplementation, or
better follow-up of pregnant women with chronic
diseases like diabetes has been proposed. Further
investigation is required to determine the effect of
possible risk factors, as this can provide a basis for
treatment, lifestyle advice, or public health interventions.Acknowledgements
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